How subcutaneous semaglutide moves through your body

Why does subcutaneous injection produce such a long-acting effect?

Semaglutide's pharmacokinetics after subcutaneous administration are unusually favourable for a once-weekly schedule. After injection into the abdomen, thigh, or upper arm, the molecule diffuses slowly from the subcutaneous depot into surrounding capillaries. This slow transit is partly deliberate: the molecule has been engineered with a fatty-acid chain that anchors it tightly to albumin, the most abundant protein in human plasma. That albumin binding (exceeding 99%) slows distribution and shields semaglutide from the enzymes that would otherwise break it down quickly.

The result is a half-life of roughly seven days, which maps neatly onto the weekly injection schedule. You can read more about the molecular design behind this on our semaglutide pharmacology page. A common misconception is that a longer-acting drug must produce a flatter, weaker effect, in reality the sustained plasma exposure is what drives the consistent appetite suppression seen across the STEP trial programme. The STEP 1 trial, published in the New England Journal of Medicine, demonstrated average weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose, an outcome that depends directly on maintaining therapeutic plasma levels between weekly doses.

Because semaglutide is metabolised by non-specific proteolysis rather than cytochrome P450 enzymes, interactions with common medicines are relatively limited, though your prescriber will still review your full medication list before approving treatment.

What happens between the injection and steady-state, and why does it take weeks to feel the full effect?

Steady-state concentration is not reached after the first injection, or even the second. With a seven-day half-life, it takes four to five half-lives to approach pharmacokinetic equilibrium, meaning most people are still accumulating drug levels through the first four to five weeks of treatment. This is one reason the Wegovy dosing schedule begins at 0.25 mg and escalates gradually, the lower starting doses allow the body to adjust while systemic exposure climbs.

Peak plasma concentration (Tmax) typically occurs somewhere between 24 and 72 hours post-injection, though the range across individuals can be wider. The subcutaneous route itself contributes to this variability: injection site, skin thickness, and local blood flow all influence absorption rate modestly. Rotating sites (as the prescribing information recommends) helps maintain consistency. More detail on correct injection technique is covered in our guide to subcutaneous semaglutide administration.

The practical implication is patience. Patients who feel little change in appetite in week one or two are not experiencing treatment failure; they are still on the ascending portion of the plasma-concentration curve. Steady-state is where the therapeutic work happens, and it arrives reliably once the escalation schedule is followed as prescribed.

Does the injection site change how well semaglutide is absorbed?

Bioavailability across the three approved injection sites (abdomen, thigh, and upper arm) is broadly comparable for semaglutide. The NHS medicines information for semaglutide confirms that all three sites are suitable, and the summary of product characteristics notes no clinically meaningful difference in overall exposure between them. That said, local blood flow does vary slightly: the abdomen tends to have faster absorption kinetics than the thigh, though the difference does not translate into a significant change in overall area-under-the-curve at steady state.

What matters more practically is rotation. Using the same small patch of tissue repeatedly can cause localised lipohypertrophy (a build-up of fatty tissue at the injection site) which can slow absorption unpredictably. Rotating within and between sites avoids this. If you want a fuller picture of the biology underlying these injection decisions, our page on whether Wegovy is intramuscular or subcutaneous covers the anatomical reasoning clearly.

One point worth noting for anyone researching supply: semaglutide products sourced outside the licensed UK supply chain carry real risks that pharmacokinetic data cannot address. Counterfeit pens may contain entirely different substances. The MHRA has issued clear public warnings on this; our page on raw pharmaceutical semaglutide explains what that term actually means and why unlicensed sources are unsafe.

How does pharmacokinetics inform the cost and practicality of Wegovy treatment?

Understanding the pharmacokinetic profile puts some practical questions in context. Because semaglutide builds in the body over weeks, missing a dose is not trivial, plasma levels drop meaningfully, and re-establishing steady state takes time. Your prescriber will advise on missed doses; the Patient Information Leaflet contains the specific guidance, and that is always the right reference rather than general estimates.

The long half-life also has implications for stopping treatment. Semaglutide does not clear the body overnight; meaningful plasma levels persist for several weeks after the final injection. This is relevant both to family planning (the MHRA advises using contraception while on GLP-1 medicines and for a wash-out period before trying to conceive) and to surgical planning, where your anaesthetist should be told about any GLP-1 treatment in advance.

For those weighing up the practical and financial side of sustained weekly treatment, our Wegovy pricing page covers what to look for in a legitimate private prescription service and what a single transparent cost should include. A prescription-only medicine with this pharmacokinetic profile needs proper clinical oversight, not just at the start, but at each dose change and repeat. That is what a consultation with our prescribers is designed to provide.